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Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy 
for inflammatory arthritis (IA).
Methods: This was a single-center, noninterventional, patient questionnaire-based study of 
adult IA patients currently receiving IV biologics. At a single visit, patients completed the 
questionnaire comprising 30 questions centered on their experience receiving an intravenously 
administered therapy to treat their IA. The questionnaire included questions on patient demo-
graphics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and 
IV). Patients rated their level of agreement with statements regarding satisfaction with current 
IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using 
a 5-point Likert scale (1= strongly disagree, 5= strongly agree).
Results: One hundred patients were enrolled and completed the survey; 66% were female and 
the mean age was 58 years. Before IV treatment, 97% of patients received information regard-
ing therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5. 
The proportion of patients with an “extremely favorable” perception of IV therapy increased 
from 33% to 71% following initiation of their current medication. Thirty-one patients had 
previously received SC therapies to treat their IA.
Conclusion: These results demonstrated an overall favorable perception of IV therapy among 
this patient population. Patients previously treated with SC therapy also had a positive shift in 
the perception of IV therapy after initiating IV therapy. Patients’ perception and preference for 
treatment options should be highly considered by the treating physician during or as part of a 
shared decision-making process.
Keywords: intravenous, patient satisfaction, arthritis, biologic therapy
Introduction
Currently, biologic agents for treating inflammatory arthritis (IA) are administered 
either as subcutaneous (SC) injections or intravenous (IV) infusions. Given the variety 
of biologic therapies available for patients with IA, patient preferences regarding the 
mode of administration may play an important role in treatment adherence.1 Factors 
that may influence patient preferences for SC or IV treatment include how the drug 
is administered (ie, self-administered at home vs traveling to a health-care setting), 
medication storage requirements, and frequency of dosing. Among patients receiving 
either SC or IV antitumor necrosis factor (TNF) therapy, individual patient prefer-
ence was reported as fundamental to the selection of a therapeutic agent and route 
of administration, both of which increased treatment success.2 In another survey 
study, patients with rheumatoid arthritis who were considering anti-TNF therapy 
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were equally receptive to both SC and IV agents.3 Results 
derived from a treatment satisfaction questionnaire (TSQM 
version II) indicated a high level of patient satisfaction with 
either SC or IV administration.2 Progressive data indicate 
that a shared decision-making process is important to the 
successful outcomes of a new treatment plan.4,5 Thus, it is 
reasonable that patient preferences for an SC or IV biologic 
be explored to assess what is optimal for both the patient’s 
and the rheumatologist’s treatment goals.
Few studies have addressed the positive or negative 
attributes associated with specific modes of administra-
tion of biologic therapies for inflammatory arthropathies. 
To address these issues, we developed a questionnaire to 
explore patient perspectives regarding treatment with an 
IV biologic. The primary objective was to obtain patient-
reported outcome (PRO) information that may be used 
to better understand the treatment perceptions of patients 
receiving IV biologics for IA.
Methods
Study design and patients
The PRO IV study was a single-center, noninterventional, 
patient questionnaire-based study conducted over ~8 weeks 
and enrolled adults with IA who were currently receiving 
therapy with IV biologics. The protocol was approved by the 
institutional review board for the site (Western Institutional 
Review Board). Each patient completed one questionnaire at 
a single infusion visit. There were no restrictions with respect 
to the IV biologic used to treat patients’ IA.
Adults with a diagnosis of IA were eligible if they were 
receiving IV biologic treatment for $3 months before 
screening, had the ability to understand and sign an informed 
consent form, were willing to complete a paper question-
naire, and could read, write, and speak English. Patients were 
excluded if they had a serious concomitant illness that could 
otherwise interfere with their ability to complete the ques-
tionnaire or if they were participating in any interventional 
investigational clinical study. Patients were selected from one 
site and informed that the study would not affect treatment. 
Written informed consent was obtained from all patients at 
a screening visit which occurred within 2 weeks before the 
visit when the questionnaire was administered.
Questionnaire
The PRO IV questionnaire comprised 30 questions devel-
oped to characterize and quantify the patients’ experience 
of receiving an IV therapy to treat their IA. The question-
naire included questions on patient demographics, disease 
characteristics for which they were receiving their current IV 
biologic therapy, medical history, previous biologic treatment 
for IA (including both self-administered SC and IV admin-
istrations), education level, insurance status, and whether 
patients discussed IV therapy with health-care professionals 
before receiving an IV therapy.
Patients were asked to rate their perception of IV biologic 
treatment as recalled from before and after receiving treat-
ment with IV therapy using a 5-point Likert scale (1= not 
favorable, 5= extremely favorable). All patients were asked 
to rate their agreement with statements regarding satisfac-
tion with their current IV biologic therapy and potential 
advantages and disadvantages of IV biologic therapy using 
a 5-point Likert scale (1=  strongly disagree, 2= disagree, 
3= neutral, 4= agree, and 5= strongly agree). Patients who 
had previously received an SC biologic therapy for their 
IA were asked additional questions assessing the potential 
reasons why they switched from SC to IV administration. 
This subgroup of patients was presented with several possible 
reasons for why they switched from an SC to an IV biologic 
for their IA, and they were asked to rate their agreement with 
the statements using the 5-point Likert scale (1= strongly 
disagree, 5= strongly agree).
The questionnaire was administered at the study visit by 
the study site coordinator. In all cases, the study visit was 
a regularly scheduled infusion visit, and the questionnaire 
was completed by the patient in a separate room before 
the infusion.
Safety
This was an observational study that did not involve the 
administration of any therapies to patients. There was no 
proactive safety data collection component; incidental, 
spontaneous reports of adverse events or serious adverse 
events that were described by the patient, either in the patient 
questionnaire or verbally to members of the clinical study 
staff during the study, were to be reported. However, no 
adverse events or other safety data were reported.
Statistical analysis
Version 3.2.1 of R and Statistical Analysis System version 
9.2 were used for all analyses. Descriptive statistics sum-
marized the questionnaire responses, means and SDs for 
continuous variables and frequencies and percentages for 
categorical variables. Bar charts were plotted for categorical 
variables (eg, favorability ratings before and after IV treat-
ment). Subgroup analyses were performed with patients 
stratified by previous use of self-administered SC treatment 
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(yes/no) to assess patient opinion on IV treatment before 
and after receiving IV therapy and perceived advantages 
and disadvantages of SC and IV treatments. McNemar’s 
test was used to evaluate the changes in perception of IV 
therapy before and after receiving treatment.
Results
Patient demographics and disease 
characteristics
One hundred patients were enrolled, with a mean age of 
58.35 years. Mean disease duration was 10.10 years; 68% 
had rheumatoid arthritis, 21% had psoriatic arthritis, 9% 
had ankylosing spondylitis, and 2% had Crohn’s disease/IA. 
Patients were, on average, obese based on a mean body mass 
index (BMI) of 30.29. The study population was ethnically 
diverse. The most common comorbidity was hypertension 
(44%). A total of 46% of patients reported graduating col-
lege or attending graduate school, and 43% graduated high 
school or attended some college. Nearly half of all patients 
were working full time (48%), with the next largest group 
being retired or unemployed (43%). All but one patient (99%) 
reported having health insurance (Medicare, Medicaid, or 
Private), while 82% of patients also said they had a prescrip-
tion plan (Table S1).
The majority of patients reported positive responses to 
the lifestyle questions: 64% used daily vitamins, 57% used 
additional supplements on a regular basis, 79% ate a bal-
anced diet (including several servings of fruits and vegetables 
daily), 85% tried to get $7 hours of sleep each night, and 
61% had a busy/active lifestyle. Among all patients, 45% 
reported exercising regularly ($3 times/week). A total of 
69% of patients rated their health as 4 or 5 (1= very poor 
health, 5= perfect health) during the previous month, and 7% 
reported a health status of 1 or 2 (Table S1); the mean ± SD 
health rating score was 3.86±0.93.
Current and previous biologic therapies 
for inflammatory arthritis
Among biologics that patients had previously used for their 
IA, the most commonly used class was anti-TNF agents 
(infliximab, 20%; etanercept, 22%; adalimumab, 19%; 
golimumab SC, 3%; golimumab IV, 1%). Patients also 
reported previous treatment with abatacept (8%), tocili-
zumab (4%), rituximab (2%), and certolizumab (1%). A total 
of 31% of patients had received SC biologic treatment before 
starting an IV biologic.
Five IV biologics were reported as current therapies for 
IA in this population: infliximab (71%), rituximab (12%), 
tocilizumab (10%), abatacept (6%), and golimumab (1%); 
mean exposures for these therapies were 4.74, 2.94, 1.43, 
3.44, and 0.42 (n=1) years, respectively. The overall mean 
duration of IV therapy was 4.07 years (range: 0.08–16.00 
years). Nearly all patients (97%) reported receiving counsel-
ing about their IV infusion therapy before initiating treatment; 
of these, 97% reported counseling from a physician (part of 
a shared decision-making experience), 37% from a nurse 
or a nurse practitioner, 92% reported that they had received 
pamphlets or other reading material in preparation for begin-
ning their IV infusion therapy, and 12% reported that they 
were directed to a website for information.
Perceptions of current intravenous 
biologic therapy for inflammatory 
arthritis
Seventy-seven percent of patients were very satisfied 
(level 5) with using an IV infusion medication (Figure 1A), 
and one patient (1%) indicated a rating of “not at all satis-
fied” (level 1). The overall mean ± SD level of satisfac-
tion with all currently used IV infusion therapies was 
4.63±0.79. On an individual therapy basis, mean scores were 
4.76±0.60 for infliximab, 4.67±0.52 for abatacept, 4.00±1.41 
for tocilizumab, 4.33±0.98 for rituximab, and 5.0 (n=1) for 
golimumab.
Patients were asked to rate their level of agreement 
(1=  strongly disagree, 5=  strongly agree) with statements 
related to receiving IV therapy for IA. Patients had the high-
est mean scores for the statements “My doctor felt strongly 
that an IV medication was the best choice for me,” “The 
doctor can adjust the dose of medication if needed,” and 
“I believe that IV medications are strong medications” 
(Table 1). Thirty-one patients had previous experience with 
self-administration of SC biologics. In general, there were 
no apparent differences between patients with previous SC 
biologic experience and those without previous SC biologic 
experience in the relative rank of agreement with these state-
ments (Table 1). However, when compared with patients 
without prior SC injection experience, patients with prior 
SC injection experience had a lower mean agreement score 
in response to the statement “I would be concerned about the 
risk of hurting or injuring myself if I had to give myself shots” 
(4.20 vs 2.77, respectively). A similar trend was observed 
in response to the statement “I don’t like needles and don’t 
like the idea of having to give myself shots” (3.99 vs 3.13, 
respectively) (Table 1).
Patients were queried in regard to their perception of IV 
therapy to treat their IA before and after starting IV therapy. 
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Table 1 Patient agreement with statements regarding use of current IV biologic therapy for IA (5-point scale: 1= strongly disagree, 
5= strongly agree)
All patients 
(n=100)
No previous 
self-injection 
(n=69)
Previous 
self-injection 
(n=31)
My doctor felt strongly that an IV medication was the best choice for me 4.55±0.67 4.51±0.72 4.65±0.55
The doctor can adjust the dose of medication if needed 4.49±0.82 4.51±0.78 4.45±0.93
I believe that IV medications are strong medications 4.24±0.78 4.25±0.85 4.23±0.62
For my lifestyle, it is easier for me to schedule an appointment at an 
infusion center than to remember when to give myself shots
4.17±1.10 4.48±0.87 3.48±1.26
I believe an IV infusion would not be painful 4.12±0.82 4.28±0.71 3.77±0.96
Other medications did not control my symptoms 4.06±0.91 4.09±0.92 4.00±0.89
The infusion center is close to my home or office, making it convenient 3.89±1.25 3.94±1.25 3.77±1.26
I would be concerned about the risk of hurting or injuring myself if I had 
to give myself shots
3.76±1.32 4.20±1.10 2.77±1.26
I don’t like needles and don’t like the idea of having to give myself shots 3.72±1.32 3.99±1.28 3.13±1.23
My co-pay or out-of-pocket cost is lower with an IV infusion medication 
than medications that i would have to administer as shots
3.53±1.00 3.65±0.94 3.26±1.09
Note: Data presented as mean ± sD.
Abbreviations: IA, inflammatory arthritis; IV, intravenous.
Among all patients, 33% had an “extremely favorable” 
perception of IV therapy before initiating their current IV 
treatment, and this increased to 71% following initiation of 
their current therapy (P,0.0001) (Figure 1B). Likewise, 
the mean ± SD favorability perception score for IV therapy 
increased from 3.73±1.21 to 4.54±0.87 after patients initiated 
their current IV infusion therapy. The increase in favorability 
among patients’ perception of their current IV therapy was 
Figure 1 Actual question: How satisfied are you with using an IV infusion medication? Patient satisfaction with IV infusion therapy (A) and favorability of IV treatment before 
and after initiating IV infusion therapy for all patients (B) and for patients with and without previous experience with SC agents (C).
Abbreviations: IV, intravenous; SC, subcutaneous.
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independent of whether they had previously received an SC 
biologic for IA (Figure 1C).
Patients with prior SC biologic experience (n=31) were 
presented with possible reasons for why they switched 
from an SC to an IV biologic. The distribution of level of 
agreement with these choices is shown in Figure 2. These 
patients agreed most strongly with the statement, “The 
medication administered by shots wasn’t working” (mean 
score ± SD: 4.03±1.08). Mean responses to the other reasons 
presented to patients were generally “Neutral” (neutral =3, 
Figure 2 Level of patient agreement with reasons for switching from SC to IV therapy for IA: (A) The medication administered by shots wasn’t working. (B) I had side effects 
to the medication administered by shots. (C) The cost of IV infusion medication was less. (D) I had difficulty remembering when to administer the shots. (E) I had difficulty 
administering the shots. (F) I didn’t like giving myself shots.
Abbreviations: IA, inflammatory arthritis; IV, intravenous; SC, subcutaneous.
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patients tending to not agree or disagree): side effects from 
SC medication (2.87), cost of IV medication (2.84), difficulty 
remembering when to administer SC medication (3.03), dif-
ficulty administering SC medication (3.00), and not liking to 
give SC injections to themselves (3.23).
Patients were presented with several possible advantages 
and disadvantages of using IV biologics and asked to rate 
how strongly they agreed (1= strongly disagree, 5= strongly 
agree) with the statements (Table 2). Of the possible advan-
tages, patients agreed most strongly with the statement “The 
medication is being administered by professionals who can 
monitor for any side effects” (mean ± SD score: 4.79±0.50). 
Patient responses were neutral toward the potential advan-
tages “Infusion therapy is less costly” (3.42±1.12) and “I take 
advantage of other activities such as shopping or going out 
to eat on days when I have to go to the infusion center” 
(3.32±1.18). Mean scores for the potential disadvantages 
that were presented to patients (eg, I have to travel to an 
infusion facility center [2.79±1.31] and the duration of the 
infusion itself takes too much time [2.47±1.15]) were all 
below 3 (neutral). This indicates that from the perspective 
of the patients, they did not strongly agree that the proposed 
statements were in fact disadvantages. No outstanding 
disadvantage to using IV biologics was identified by these 
patients. There were no apparent differences in the responses 
to either potential advantages or disadvantages between 
patients who had previously used SC biologics and those 
who had not (Figure 2).
All patients were asked to rate their level of agreement 
with potential advantages and disadvantages of receiving 
their IA medication by an SC injection (Table 3). All of the 
statements describing the potential benefits of SC treatment 
Table 2 Patient agreement with potential advantages and disadvantages to receiving IV infusion therapy for IA (5-point scale: 1= strongly 
disagree, 5= strongly agree)
All patients 
(n=100)
No previous 
self-injection 
(n=69)
Previous 
self-injection 
(n=31)
Potential advantages
The medication is being administered by professionals who can monitor for 
any side effects
4.79±0.50 4.77±0.52 4.84±0.45
The staff at the infusion center keeps track of when I need my next dose of 
medication and my next doctor’s appointment and keeps me on schedule
4.69±0.61 4.67±0.68 4.74±0.44
The staff of medical professionals can assess how I am doing 4.68±0.57 4.67±0.59 4.71±0.53
The visit for my infusion provides another assessment beyond my regular 
doctor visit
4.45±0.70 4.36±0.75 4.65±0.55
i want to have a health-care professional administer the medication to me 4.44±0.81 4.55±0.74 4.19±0.91
Infusion therapy is more consistent with my lifestyle 4.21±0.99 4.39±0.84 3.81±1.17
With IV therapy, I don’t have to fear about injecting myself 4.20±1.03 4.48±0.87 3.58±1.12
I like being able to socialize with the staff and other patients at the infusion unit 4.15±0.90 4.22±0.91 4.00±0.89
The staff of medical professionals at the infusion center can also monitor my 
other medical conditions
4.13±0.96 4.16±0.93 4.06±1.03
The infrequent dosing is an advantage 4.09±0.90 4.22±0.81 3.80±1.03
Infusion therapy is less costly 3.42±1.12 3.58±1.12 3.06±1.06
I take advantage of other activities such as shopping or going out to eat on 
days when I have to go to the infusion center
3.32±1.18 3.39±1.24 3.16±1.04
Potential disadvantages
I have to travel to an infusion facility 2.79±1.31 2.74±1.29 2.90±1.37
The cost of the infusion, such as the co-insurance or co-pay costs 2.55±1.22 2.57±1.23 2.52±1.21
The infusion itself takes too much time 2.47±1.15 2.46±1.17 2.48±1.12
Frequent scheduling issues, such as time off work, finding a babysitter, etc 2.30±1.16 2.33±1.18 2.23±1.12
The cost of going to the infusion center, such as gas, parking, etc 2.26±1.14 2.22±1.15 2.35±1.14
Missing several hours from work or school 2.23±1.12 2.32±1.13 2.03±1.08
I don’t like seeing the IV needle 2.22±1.12 2.26±1.17 2.13±0.99
The loss of vacation days from work 2.15±1.09 2.23±1.11 1.97±1.02
The need for IV treatment reminds me that I am sick 2.15±1.15 2.13±1.16 2.19±1.14
I don’t like being in a setting with other people who may be very ill 1.97±0.95 1.97±1.00 1.97±0.84
The IV infusion is difficult since I have poor veins 1.92±1.08 1.94±1.11 1.87±1.02
Note: Data presented as mean ± sD.
Abbreviations: IA, inflammatory arthritis; IV, intravenous.
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received mean scores ,3 (neutral). The opposite was 
observed for statements regarding potential disadvantages 
of receiving their medication as an SC injection, with mean 
scores .3. Patients agreed most strongly with the potential 
disadvantage statement of “There is no medical staff 
immediately available if I experience side effects from the 
medication” (mean ± SD disadvantage score: 4.08±1.10). 
Mean patient responses to the potential disadvantages and 
advantages of receiving treatment as an SC injection were 
similar whether the patients had previous experience with 
self-injection (Table 3).
Thirty-nine patients reported that they had to take time 
off from work to receive their IV infusion. The majority of 
these patients agreed or strongly agreed that it was not a 
problem to miss time from work to receive their infusion; few 
patients agreed with statements indicating difficulties with 
missing time from work to receive their infusions (Table 4). 
Sixty-one percent of all patients reported that travel time to 
Table 3 Patient agreement with potential advantages and disadvantages of self-administration of SC therapy for IA (5-point scale: 
1= strongly disagree, 5= strongly agree)
All patients 
(n=100)
No previous 
self-injection 
(n=69)
Previous 
self-injection 
(n=31)
Potential advantages
I could avoid a trip to the doctor’s office 2.68±1.25 2.67±1.30 2.71±1.16
i would use less health-care resources 2.63±0.99 2.62±0.99 2.65±1.02
Injections (shots) are less costly for me 2.60±0.95 2.56±0.98 2.68±0.87
I have more control of when I take my medicine 2.36±1.14 2.32±1.19 2.45±1.03
I am comfortable giving myself shots 2.33±1.33 2.14±1.36 2.74±1.18
I feel I am in more control of my disease 2.26±1.19 2.17±1.24 2.45±1.09
I can remember to give myself shots vs remembering an appointment 2.25±1.13 2.13±1.17 2.52±1.00
I don’t want to be around others when getting a medical treatment 2.03±0.95 1.99±0.98 2.13±0.88
Potential disadvantages
There is no medical staff immediately available if I experience side effects 
from the medication
4.08±1.10 4.10±1.18 4.03±0.91
I would worry about the refrigeration, keeping refrigerated while traveling, 
ordering the medication from the pharmacy, etc
3.89±1.19 3.91±1.27 3.84±1.00
I am not comfortable injecting myself 3.88±1.16 4.09±1.15 3.42±1.06
The doctor may not be able to adjust the dose of medication with the shot 3.85±1.07 3.87±1.16 3.81±0.87
I would worry about disposing of the needles 3.71±1.23 3.80±1.26 3.52±1.15
I need to remember when to give myself shots 3.70±1.21 3.59±1.33 3.94±0.85
I would worry about having needles in the house (potential danger to 
children and pets)
3.55±1.26 3.67±1.29 3.29±1.16
There is no opportunity for socialization, such as talking with the staff or 
other patients with my condition
3.50±1.17 3.55±1.23 3.39±1.02
My out-of-pocket costs might be higher (co-pay, co-insurance) 3.27±1.01 3.32±1.03 3.16±0.97
I have too many other medical conditions to take care of already 3.29±1.18 3.30±1.28 3.26±0.96
Note: Data presented as mean ± sD.
Abbreviations: IA, inflammatory arthritis; SC, subcutaneous.
Table 4 Patient agreement with statements regarding difficulty missing time from work, among those who miss time from work to 
receive infusions for IA (n=39)
Strongly 
agree
Agree Neutral Disagree Strongly 
disagree
How difficult is it to get the time off from work, n (%)
Not a problem – the company (or supervisor) is very understanding 21 (53.8) 13 (33.3) 5 (12.8) − −
Not a problem – I make up the time later in the week 15 (38.5) 7 (17.9) 11 (28.2) 3 (7.7) 3 (7.7)
Slight problem – I always have to negotiate when I can leave and when 
the time will be made up
2 (5.1) 2 (5.1) 10 (25.6) 10 (25.6) 15 (38.5)
It’s a problem – I need to sneak out early or call in sick to make the visit 1 (2.6) 1 (2.6) 10 (25.6) 9 (23.1) 18 (46.2)
It’s a problem since I don’t get paid for the time I miss at work 2 (5.1) 4 (10.3) 8 (20.5) 9 (23.1) 16 (41.0)
Note: Data presented as n (%).
Abbreviation: IA, inflammatory arthritis.
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the infusion center was ,30 minutes, while 36% reported 
travel time between 31 and 60 minutes, and 3% of patients 
reported that their travel time was .60 minutes. Mean agree-
ment scores (1= strongly disagree, 5= strongly agree) for the 
statements “Not a problem; my company or supervisor is 
understanding” and “Not a problem; I make up the time later 
in the week” were 4.41±0.72 and 3.72±1.28, respectively, 
indicating agreement; whereas, mean agreement scores for 
the statements “It’s a problem; I need to sneak out early or 
call in sick to make the visit” and “It’s a problem; I don’t 
get paid for the time I miss at work” were 1.92±1.04 and 
2.15±1.23, respectively, indicating less agreement by the 
patients with these statements.
Discussion
There are a variety of factors that influence a patient’s deci-
sion in regards to choosing therapy for their IA. Among 
the available choices are biologic drugs administered either 
as an SC injection or IV infusion. A key component in the 
decision-making process is the patient–physician relation-
ship. It is increasingly evident that the physician should 
discuss the advantages and disadvantages of each treatment 
option with the patient.5–7 As the results of this study indicate, 
some patients may perceive meaningful differences between 
treatment modalities. Other patients may identify advantages 
with a certain route of administration based on individual 
preferences and perceptions. The results presented here 
support a shared decision-making process between the patient 
and the physician, in which the patient is offered the available 
options in sufficient detail, and then the patient’s perception 
and preference for treatment options are highly considered.
In this study of 100 patients currently receiving IV 
therapy for IA, there was a high level of satisfaction 
among all patients with regard to their experience with IV- 
administered biologic therapy. A total of 90% of patients 
ranked their satisfaction with IV therapy as 4 or 5, with 77% 
ranking satisfaction as 5 (very satisfied). These results align 
with a recent publication in which 82% of patients receiving 
an IV biologic to treat an autoimmune disease (ie, ankylosing 
spondylitis, rheumatoid arthritis, psoriatic arthritis, psoriasis, 
Crohn’s disease, or ulcerative colitis) indicated a preference 
for an IV-administered treatment over an SC-administered 
treatment.8 In our study, overall, the decision to use IV 
therapy was influenced primarily by the patients’ perception 
of efficacy and the opinion of their treating physician. Patients 
also tended to strongly agree with the statement that it was 
easier to schedule appointments for their infusions rather than 
remember to self-administer SC injections. Among patients 
who switched from an SC therapy to an IV therapy, the 
primary reason for switching (among those in the question-
naire presented to the patient) pertained to efficacy. A total 
of 67.8% of patients either agreed or strongly agreed that 
the switch to IV infusion was related to the SC medication 
“not working”. The reason for switching with the next high-
est level of agreement (agreed or strongly agreed) was that 
patients did not like giving themselves SC injections (38.7%). 
Among other possible reasons, the majority of patients were 
neutral, disagreed, or strongly disagreed regarding adverse 
events (80.7%), lower cost of IV medication (93.6%), diffi-
culty remembering when to administer SC injections (77.4%), 
or difficulty administering the SC injection (67.7%) as the 
rationale for switching from SC to IV.
There was no apparent difference in the degree of 
favorability reported for receiving IV therapy between 
the patients who had previously used SC biologic therapy 
and those who had not received prior SC therapy. Overall, 
patients who had previously received SC therapy and later 
switched to IV therapy identified multiple benefits of infu-
sion therapy which were not available to them while they 
were self-injecting. Although the differences were not 
statistically significant, it is interesting to note that the four 
“advantage” statements with the highest agreement scores 
overall (among all patients) had even higher agreement scores 
among patients with prior SC injection experience. Overall, 
these highest-ranking potential advantages of IV treatment 
suggest that constant professional reinforcement of disease 
management, readily available health-care resources to assist 
with any problem, and relationships developed with the staff 
are meaningful to patients receiving IV biologic treatment. 
These factors should be discussed as part of the shared 
decision-making process.
Patients in our study had a more favorable perception 
of IV therapy after receiving this therapy compared with 
their recollection of how they felt about it before receiving 
IV therapy. This relative shift in perception was observed 
for both patients who had, and those who had not, received 
SC biologic therapy previously. Regarding their use of 
IV medication, reasons with the greatest agreement score 
pertained to physician input on what the best therapy was 
for the patients and that the physician would be able to 
adjust the dose of medication as needed. These reasons 
were the highest ranking independent of prior SC injection 
experience. Similarly, among the potential advantages of 
IV therapy, the highest-ranking factor pertained to the level 
of health care provided as a component of the IV infusion 
experience. Again, highest-ranking potential advantages 
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were independent of prior SC injection experience. These 
results suggest that patients had improved control of their 
disease after receiving IV therapy and may have developed 
a relationship with the infusion provider. Likewise, patients 
may have bonded with the nurses, medical assistants, and/or 
physicians at the site where this study was conducted. It was 
observed that the average time patients had received their IV 
therapy was .4 years, supporting the potential of a relation-
ship-building aspect. Finding the time to have a monthly, 
bi-monthly, or every-6-month infusion did not appear to be 
a problem for the majority of patients. The need to schedule 
the time off, either professionally or personally, seemed to 
be an acceptable part of the infusion treatment plan. In some 
instances, patients reported a level of positivity toward being 
able to take a break from a schedule of normal life activities 
to come in for an infusion where all of the work was done by 
the staff and the experience was favorable. Of note, nearly all 
patients reported having been educated about their IV infu-
sion before starting treatment. Most of these patients (97%) 
reported receiving consultation from a physician; 37% also 
spoke with a nurse or a nurse practitioner. A survey of Belgian 
patients with  rheumatoid arthritis and rheumatologists (the 
Be-Raise study) demonstrated that patients’ primary concerns 
were centered on effectiveness of treatment.9 There was a 
notable difference in the patient-reported satisfaction with 
IV therapy (52.4%) and the perceived patient satisfaction 
reported by physicians (29.9%).9 These results also support 
a shared decision-making conversation with effective discus-
sions between health care professionals and patients before 
initiating therapy being a critical component of the shared 
decision-making process regarding drug therapy choices.
The relative importance of patient perspective in treat-
ment preferences of IA has also been assessed in a younger 
population. In a study of patients aged 16–25 years who were 
diagnosed with a spectrum of IA diseases, it was determined 
that leading a “normal” life was an important overall goal 
from the patients’ perspective.10 Hart et al also found that 
young patients need active encouragement to discuss their 
treatment concerns and difficulties with the care team,10 a 
conclusion that coincides with our findings that support a 
shared decision-making approach.
This study was conducted at a single site, which may limit 
the generalizability of the results. For example, only 38% 
of the population was reported as Caucasian and 28% were 
reported as African American. This distribution is different 
from a broader US-based IA population.11 Furthermore, 
some of the items in the questionnaire relied on the patients’ 
recall of their prior perceptions and experiences. Patients also 
tended to have positive perceptions of their current health 
status with IV therapy (majority rating of 4 or 5, with 5 being 
perfect health), possibly suggesting an overall positive atti-
tude toward IV infusion therapy. Despite these limitations, 
our results demonstrate the characteristics and perceptions 
of patients with IA receiving ongoing IV therapy.
Overall, the 100 patients who had received infusion 
therapy for $3 months for their IA had a positive perception 
regarding IV therapy. Of note, patients previously treated 
with SC therapy had a similar positive perception. This 
would suggest that physicians should strongly consider that 
patients may be open and amenable to an infusion therapy 
option as part of a shared decision discussion. Furthermore, 
this illustrates the value of an outpatient infusion center where 
there are experts, a consistent and knowledgeable staff, and 
a comfortable environment which may be desirable and 
beneficial to patients.
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Table S1 Baseline demographic and disease characteristics
Demographics Patients (n=100) Disease characteristics Patients (n=100)
Age, years 58.35±14.64 Disease duration, years 10.10±8.14
Female 66 Disease duration range, years 0.67–45.00
Weight, kg 85.03±19.69 Disease diagnosis
BMI, kg/m2 30.29±5.98 rheumatoid arthritis 68
race Ankylosing spondylitis 9
caucasian 38 Psoriatic arthritis 21
African American 28 crohn’s disease/iA 2
latino/hispanic 22 Medical history
Asian/Pacific Islander 1 heart disease 7
Not identified 11 Congestive heart failure 1
education Hypertension 44
grade school 3 Insulin-dependent diabetes 4
Some high school 3 Non-insulin-dependent diabetes 11
High school graduate 19 stroke 2
Some college 24 Peripheral vascular disease 5
College graduate 29 skin cancer 8
graduate school 17 cancer 5
Trade school 5 hepatitis 3
Employment status Tuberculosis 0
Full-time job 48 chronic infection 3
Part-time job 7 stomach/Duodenal ulcer 9
student 1 COPD/Emphysema 5
homemaker 1 current health scorea
Retired/unemployed 43 1 2
health insurance 2 5
Medicare 39 3 24
Medicaid 7 4 43
Private 72 5 26
Notes: Data presented as n or mean ± sD. aPatients were asked: “On a scale of 1–5, how would you rate your health over the past month?” 1= Very poor health, 5= Perfect 
health.
Abbreviations: BMI, body mass index; COPD, Chronic Obstructive Pulmonary Disease; IA, inflammatory arthritis.
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